认知行为疗法对失眠作为自杀预防策略的系统回顾和元分析
Systematic review and meta-analysis of cognitive behavioral therapy for insomnia as a suicide prevention strategy
该研究通过系统回顾和元分析,发现认知行为疗法(CBT-I)在减少失眠患者的自杀意念方面有一定效果,但自杀行为和死亡率变化不大。研究强调了失眠作为自杀风险因素的重要性,并指出数字自动化和简短版CBT-I可能更适合大规模应用。
该综述和元分析提供了认知行为疗法在自杀预防中的有效性证据,有助于临床实践和政策制定。
Main
Suicide remains a major public health issue and is among the leading causes of death worldwide, accounting for an estimated 746,000 deaths in 20211. Although recent projections suggest a modest global decline in suicide deaths by 2050, this reduction is insufficient to meet the 2030 Sustainable Development Goals target of a one-third reduction2. Suicidal ideation (that is, thoughts of suicide with or without suicidal intent)3 comprises a major risk factor for suicide attempts and deaths4. Yet, only about 30% of individuals experiencing suicidal thoughts, plans or attempts in the past year are estimated to seek or engage with mental health services5. In addition, recent evidence shows that 50–60% of individuals do not disclose their suicidal thoughts and behaviors to others6, leaving many potentially untreated. Thus, identifying and targeting modifiable risk factors may represent a valuable strategy.
Accumulating evidence has established insomnia as an independent, modifiable risk factor for suicidal ideation and behaviors7, an association noted over a century ago as contributing to a ‘very great wastage of human life (…) which might to a great extent be prevented’8. Insomnia—characterized by difficulties falling and/or staying asleep, early morning awakenings and daytime impairment—affects approximately one in ten individuals in the general population9. Given its modifiability and high prevalence, it represents a potentially promising target for suicide prevention.
Cognitive behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment for chronic insomnia among adults10. As a multicomponent intervention, it incorporates strategies such as sleep hygiene education, cognitive restructuring, sleep restriction and stimulus control. Meta-analytic evidence indicates that CBT-I is effective not only in treating insomnia in individuals with comorbid mental health disorders11,12 but also in concurrently reducing comorbid mental health symptoms12. Whether similar benefits extend to suicidal ideation and behaviors is an area of increasing research interest, although the evidence remains poorly characterized. This marks a relevant gap from a public health perspective, given that scalable formats of CBT-I, such as digital fully automated and brief behavioral versions, offer cost-effective adjunct approaches to standard in-person therapy13,14.
Recent evidence suggests that suicidal ideation may be reduced not only through suicide-focused psychotherapies15 but also through interventions addressing sleep. In line with this, two previous meta-analyses indicate that interventions targeting sleep may have small beneficial effects on suicidal ideation16,17. However, these studies combined various sleep disorders (for example, nightmares, hypersomnia and insomnia) and different pharmacological and behavioral interventions, introducing considerable heterogeneity and limiting interpretability regarding the effects of CBT-I. Moreover, neither meta-analysis examined long-term effects or potential moderators of treatment effects, such as intervention delivery format or population (for example, community versus clinical samples). Finally, relatively few CBT-I trials (k = 3 and 7)16,17 were synthesized, and unpublished data were not included. Building on the availability of unpublished data and newly published trials, the present meta-analysis aimed to quantify the effects of CBT-I, compared with control conditions, on suicidal ideation severity, suicidal behaviors and suicide deaths in adults with insomnia.
Results
Of 1,457 records screened, we included 19 randomized controlled trials (RCTs)18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36 (Fig. 1) in the systematic review encompassing 4,974 randomized adults (66% women). Reasons for exclusion after full-text screening are provided in Supplementary Information, section 1. Three trials30,33,34 selectively enrolled individuals with current/recent suicidal ideation, and one trial23 enrolled outpatients with present suicidal behaviors. Individuals with a recent suicide attempt or at high suicide risk were generally excluded (Supplementary Information, section 2). Of three included unpublished trials18,29,30, one was terminated owing to recruitment failure30. Eleven trials were conducted in the USA, and no trial was industry-funded (Supplementary Information, section 3). The number of trials using therapist-delivered CBT-I and self-guided digital CBT-I was balanced. Details regarding the intervention and control conditions are provided in Supplementary Information, section 4. Eleven trials were conducted in patient populations. Across trials reporting race/ethnicity, participants were predominantly White. Participant and study characteristics trials are summarized in Table 1 and in Supplementary Information, section 5. Outcome measures and measurement timepoints are listed in Table 2 and in Supplementary Information, section 6, respectively.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 flowchart. SB, suicidal behaviors; SI, suicidal ideation. *SLEEPI, Systematic Living Evidence Evaluation of Psychotherapies for Insomnia. †Thirty-one reports were identified through the systematic search, namely 17 journal articles, 12 clinical trial records, 1 study protocol and 1 conference abstract. Eighteen additional reports of already included studies were identified through the following sources. Contact with study authors: 1 thesis chapter, 3 publications. Referenced within included publications: 5 clinical trial registry records, 5 study protocols. Uploaded to clinical trial registry records: 2 study protocols. Preprint platform (Research Square): 1 study protocol, 1 preprint.
Compared with control conditions, CBT-I was associated with a 23% reduction in suicidal ideation severity post-intervention (ratio of means (RoM) 0.77 (95% confidence interval (CI) 0.66–0.90), P = 0.0009; I2 = 0%; 95% prediction interval (PI) 0.65–0.91; 16 studies). Table 3 provides a summary of the results of all meta-analyzed outcomes. Figure 2 provides the forest plots for suicidal ideation severity at each timepoint, while Supplementary Information, section 7, provides the forest plots for the secondary outcomes at each timepoint. A narrative synthesis is provided for three trials regarding suicidal ideation severity (Supplementary Information, section 8.1) as two had non-estimable effects26,31 and one reported a composite outcome of suicidal ideation and behaviors23. These trials were either insufficiently powered23,31 or showed results largely consistent with the meta-analysis26. We did not find evidence for publication bias, as indicated by the contour-enhanced funnel plot (Supplementary Information, section 9), and the regression test for funnel plot asymmetry was not significant. Seventy-two percent of the trials were judged to have some concerns regarding risk of bias for this outcome, followed by 17% at high risk and 11% at low risk (Supplementary Information, section 10). Sensitivity analyses that excluded trials with a high overall risk of bias, >20% dropout, waitlist control group or a single questionnaire item yielded similar results (Supplementary Information, section 11). Attrition per trial and timepoint are shown in Supplementary Information, section 12. Overall, the evidence certainty was high (Supplementary Information, section 13). Supplementary meta-analyses of suicidal ideation severity using Hedges’ g as the effect size are provided in Supplementary Information, section 14. Subgroup analyses indicated that the effects were not moderated by age group, intervention delivery format, population or whether trials selectively recruited participants with recent/current suicidal ideation (Supplementary Information, sections 15.1–15.4).
a, Forest plot of suicidal ideation severity at post-intervention, including N = 3,849 participants18,19,20,21,22,24,25,27,28,29,30,32,33,34,35,36. b, Forest plot of suicidal ideation severity at 1–3-month follow-up, including N = 384 participants18,22,32,34,35. c, Forest plot of suicidal ideation severity at 5–6-month follow-up, including N = 2,473 participants19,21,24,25,28,29,34. d, Forest plot of suicidal ideation severity at 12-month follow-up, including N = 2,503 participants19,21,25,27,28. In a–d, under the columns ‘Weight (common)’ and ‘Weight (random)’, each full-stop entry (.) indicates that the weight is not applicable (that is, the common-effect model has no random-effects weight, and the random-effects model has no common-effect weight). The forest plots show the results of common- and random-effects meta-analyses (two-sided tests with no adjustment for multiple comparisons). The random-effects model is the pre-specified model used for inference. Data are presented as effect size (RoM) with 95% CI. Square size reflects study weight in the meta-analysis; diamonds denote the pooled effect size estimate. P values are provided in Table 3.
Meta-analyses of the secondary outcomes post-intervention showed significant reductions in the CBT-I group, compared with control conditions, in ISI score (mean difference (MD) −4.09 (−5.09 to −3.10), P < 0.0001; I2 = 87.1%; 95% PI −8.01 to −0.18; 17 studies) and depression severity (standardized mean difference (SMD) −0.42 (−0.54 to −0.29), P < 0.0001; I2 = 59.9%; 95% PI −0.82 to −0.01; 17 studies). The SMD in depression severity post-intervention significantly moderated changes in suicidal ideation severity post-intervention (estimate = 0.42 (0.02–0.81), P = 0.037; Supplementary Information, section 15.5). However, this association was no longer significant after excluding the terminated trial30 identified as an outlier (P = 0.68) (Supplementary Information, section 15.5.1). The MD in ISI score (or SMD in insomnia severity) and the percentage of women did not moderate changes in suicidal ideation severity post-intervention (Supplementary Information, sections 15.6–15.8).
Regarding suicidal ideation severity at follow-ups, no significant differences were found between CBT-I and control groups, and the evidence certainty ranged from very low to moderate (Supplementary Information, section 13).
Regarding suicidal behaviors, four trials used interviews (excluding Fagundes and colleagues23; Supplementary Information, section 8.1), while five others used adverse event reporting. Across nine trials, two participants in the CBT-I groups reported suicide attempts, compared with none in the control conditions. No suicide deaths were recorded (k = 9).
Hopelessness was assessed in two trials, and there was no evidence for a difference between CBT-I and control conditions (Supplementary Information, section 8.2).
Discussion
To our knowledge, this is the most comprehensive evidence synthesis on the effects of CBT-I on suicidal phenomena, incorporating both published and unpublished data. Compared with control conditions, CBT-I was associated with a 23% reduction in suicidal ideation severity post-intervention. Fewer trials included follow-up assessments, and no significant differences between CBT-I and control groups were found. Suicidal behaviors were very rare: across nine trials, two participants reported a suicide attempt in the CBT-I group. No suicide deaths were recorded.
The modest reduction in suicidal ideation severity following CBT-I is consistent with recent meta-analyses showing that psychotherapies targeting related mental health conditions (for example, depression) can reduce suicidal ideation15, while sleep interventions may also have beneficial, albeit smaller, effects16,17. These findings are of potential public health and clinical value. Only about 30% of individuals experiencing suicidal thoughts, plans or attempts in the past year are estimated to seek or engage with mental health services5, with perceived stigma contributing to this low rate. Addressing less stigmatized issues such as insomnia may offer an indirect avenue for reaching individuals who would likely not seek care for suicidal ideation directly.
The present meta-analysis extends a previous evidence synthesis17 by including 12 additional CBT-I trials and examining potential moderators of treatment effects. We were unable to assess hopelessness as a moderator owing to insufficient data, and we did not find evidence that the reduction in suicidal ideation severity was moderated by changes in insomnia or depression severity. These findings should be interpreted cautiously, as such analyses are susceptible to ecological fallacy. Individual participant data meta-analyses will be needed to clarify whether, and to what extent, improvements in insomnia are associated with meaningful reductions in suicidal ideation. Evidence from an included trial27 suggests that insomnia remission may represent a pathway through which CBT-I alleviates and prevents suicidal ideation.
It is possible that insomnia represents an upstream target for suicidal ideation. Indeed, theory-driven studies show that insomnia contributes to suicidal ideation through pathways such as feelings of defeat and entrapment37 (see the integrated motivational–volitional model of suicidal behavior)38 as well as social disconnection39 (see the interpersonal theory of suicide)40. Other possible mechanisms include depression41, nightmares41, hyperarousal41 and the effects of being awake during the biological night. Notably, incident suicide risk has been found to be threefold higher between midnight and 6 a.m. than any other time of day, after adjusting for population sleep–wake timing42. The recent ‘Mind after Midnight’ hypothesis43 proposes that being awake at night may increase vulnerability to suicide owing to changes in mood regulation, attentional biases, reward processing and executive functioning. In this regard, CBT-I may help reduce suicidal ideation by stabilizing sleep–wake patterns, a mechanism that has been associated with reduced psychological distress44. Future adequately powered trials should examine these potential pathways.
Should future research confirm that insomnia remission is essential for alleviating and preventing suicidal ideation27, therapist-delivered, in-person CBT-I is likely the most effective delivery format and may be best suited to suicide prevention efforts among individuals at elevated suicide risk45. However, accessibility represents a major barrier, and expanding this model is unlikely to be a prioritized path in health systems. Consequently, self-guided digital CBT-I and brief in-person programs have emerged as complementary strategies to extend the reach of effective care at scale13,14,46. Such formats, particularly fully automated digital CBT-I, are well suited to earlier preventive stages, where scalable delivery across primary care and community settings means that even modest reductions in suicidal ideation could yield meaningful public health impact. Recent evidence indicates that culturally tailored digital CBT-I improves engagement with the program47, which highlights the importance of culturally tailored implementation and aligns with the call for suicide prevention to be collaborative, culturally informed and inclusive across real-world contexts48. Meta-analytic evidence indicates that self-guided digital interventions targeting suicidality and depression have modest beneficial effects on suicidal ideation49, which is consistent with the present findings on self-guided digital CBT-I. We found no evidence that this delivery format and therapist-delivered CBT-I differed in their effects on suicidal ideation severity. Nevertheless, the use of self-guided CBT-I in suicide prevention contexts requires careful ethical consideration. Given the absence of direct clinical oversight, such formats are most appropriate when integrated into broader care pathways that include safety monitoring and clear referral routes to crisis services, and should be avoided as stand-alone interventions in populations at elevated suicide risk. Indeed, engagement with the self-guided digital format may be an issue (Supplementary Information, section 16) in certain populations at higher suicide risk such as individuals with severe mental illness50, where digital poverty and intervention complexity could pose barriers to engagement51. For such populations where close clinical supervision is warranted (for example, in psychiatric inpatient settings), therapist-delivered CBT-I is a more feasible and appropriate choice46. Nevertheless, CBT-I remains underutilized in clinical practice, where treatment with sleep medications is common52. Some evidence suggests that zolpidem may mitigate suicidal ideation among individuals with severe insomnia53, which may be particularly useful in acute or high-risk clinical settings in which speed of response is an important consideration. However, sleep medications should be used only short term10, given their poor tolerability and unproven long-term efficacy54.
Evidence certainty for a modest reduction in suicidal ideation severity following CBT-I was high, which was supported by sensitivity analyses addressing study limitations (for example, high attrition). We limited inclusion to RCTs to obtain the most reliable estimates of efficacy. We found no evidence of publication bias, and the risk of bias owing to missing results was minimized through an extensive search strategy and the inclusion of unpublished data. Nevertheless, certain limitations need to be considered. First, only three trials included in the meta-analysis selectively enrolled participants with current/recent suicidal ideation. Individuals at high suicide risk (for example, recent suicide attempt) were generally excluded from trial participation, which may have masked the effects. Notably, one adapted face-to-face CBT-I trial35 in inpatients with severe psychiatric disorders, where elevated suicide risk was not an exclusion criterion, had the largest reduction in suicidal ideation severity (78%) among the included trials, suggesting that greater effects may be achievable in higher-risk populations. While excluding patients at high suicide risk may be considered necessary in certain contexts for regulatory, ethical or liability reasons, several design strategies may allow higher-risk populations to be studied while maintaining scientific rigor and participant safety, including time-to-event designs, sample enrichment with patients at elevated risk and the provision of usual care rather than no treatment in the comparator arm (for a review, see Wilkinson et al.55). Future trials are therefore encouraged to consider enrolling individuals at elevated suicide risk such as patients recently discharged from psychiatric hospitals56 and those with a history of self-harm57. Second, five trials relied on adverse event reporting for suicidal behaviors. Given that an estimated 50–60% of individuals do not disclose their suicidal thoughts and behaviors to others6, it is possible that not all incidents were identified. Third, suicidal ideation is highly dynamic and can fluctuate substantially over the course of hours, as demonstrated in ecological momentary assessment studies58. Assessments conducted only at limited timepoints may therefore fail to capture clinically meaningful short-term changes and mask the rapid transition between suicidal states. Future trials should consider incorporating ecological momentary assessment to provide a more temporally sensitive assessment of treatment-related changes in suicidal ideation. Fourth, although suicidal ideation is a predictor for suicidal behaviors4, relying on suicidal ideation alone may not be sufficient to identify individuals at high suicide risk59. To address this limitation, the suicide crisis syndrome has been proposed as an acute suicidal diagnosis describing a pre-suicidal state characterized by entrapment, affective disturbance, loss of cognitive control, hyperarousal and social withdrawal60. The combination of suicidal ideation and suicide crisis syndrome may be more informative for detecting individuals at high suicide risk than either construct alone59. Future trials should therefore consider incorporating assessments of both constructs. Notably, the suicide crisis syndrome integrates well with the ‘Mind after Midnight’ hypothesis described earlier43. Fifth, among trials reporting race/ethnicity, participants were predominantly White (52–100%), limiting generalizability to other groups. This is a particularly important gap, given recent evidence showing that, compared with majority populations, individuals from ethnic minority backgrounds are at elevated suicide risk, particularly indigenous populations61. Whether the beneficial effects of CBT-I on suicidal ideation extend to ethnic minority groups remains unclear and represents a key direction for future trials, which should prioritize the inclusion of diverse ethnic populations and consider culturally tailored adaptations of CBT-I. Finally, the long-term effects of CBT-I on suicidal ideation severity remain uncertain, particularly at the 1–3-month and 12-month follow-ups, which were judged to have very low and low certainty of evidence, respectively.
In conclusion, there is high certainty of evidence that CBT-I modestly reduces suicidal ideation severity post-intervention. While suicidal ideation is distinct from suicidal behaviors and suicide deaths, CBT-I could be used to augment suicide prevention strategies. Larger trials in high-risk populations are needed to determine if and how CBT-I may facilitate reductions in suicidal behaviors.
Methods
This systematic review and meta-analysis is reported following the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines62. The present systematic review and meta-analysis was prospectively registered with PROSPERO (CRD420250628820) and conducted following a published study protocol63. Amendments made to the protocol are summarized in Supplementary Information, section 17.
Data sources and search strategy
We systematically searched Medline, Embase, Cochrane Library, PsycInfo and ClinicalTrials.gov for records published from inception until 23 March 2025, without language restrictions, to identify published and unpublished RCTs. Further eligible records were sought through backward and forward citation searches using the citationchaser Shiny app64 (Supplementary Information, section 18.7). In addition, the Systematic Living Evidence Evaluation of Psychotherapies for Insomnia (SLEEPI) database (https://osf.io/c82xu/; last search on 15 December 2025) was searched. The searches were performed by one reviewer (C.T.) with a librarian. The full search strategy is provided in Supplementary Information, section 18. Titles/abstracts and full texts were screened independently and in duplicate (C.T. and C.L.S.), and disagreements were resolved through discussion. Details regarding record management and screening can be found in the protocol63. One non-English article23 was translated using DeepL next-gen65.
Eligibility criteria
We included parallel-group RCTs comparing CBT-I, in any setting or delivery format, with control conditions with no presumed strong effect on insomnia (that is, placebo, sleep hygiene education, self-help, waitlist and no treatment). CBT-I was required to include stimulus control or sleep restriction. CBT-I could be combined with other treatments if the control group received the same treatment. Participants had to be adults (≥18 years) with insomnia, with or without comorbidities, according to diagnostic criteria (that is, the Diagnostic and Statistical Manual of Mental Disorders, the International Classification of Sleep Disorders or Diseases), or a validated, clinically meaningful screening score. RCTs were included if participants younger than 18 years were recruited but the average age was ≥18 years. Studies were included if they either enrolled participants with suicidal ideation/behaviors or reported the primary outcomes. Studies measuring suicidal ideation with one item were included.
Outcomes, data extraction and data handling
Two reviewers (C.T. and C.L.S.) independently and in duplicate extracted data for the following variables using a pre-defined Excel sheet: authors, publication year, country, number and mean age of randomized participants, percentage of women, population type, race/ethnicity, number of follow-up assessments, outcome measures, funding sources, content in CBT-I and control conditions, inclusion criteria for insomnia and inclusion/exclusion criteria for suicidal ideation/behaviors. Where available, we also extracted data on treatment adherence in the CBT-I groups, psychiatric comorbidities and attrition.
Primary outcomes included suicidal ideation severity (that is, frequency, intensity and/or duration of suicidal thoughts), suicidal behaviors (suicide attempts and/or preparatory behaviors) and suicide deaths, assessed post-intervention and at follow-ups (grouped post hoc into 1–3 months, 5–6 months and 12 months post-intervention). Secondary outcomes included insomnia severity, depression severity and hopelessness. Outcome data were independently and in duplicate extracted for 20% of the trials by C.T. and C.L.S. (94.39% agreement rate). Data from the remaining trials were extracted by C.T. and verified by C.L.S. and E.H. Continuous data were extracted for all primary and secondary outcomes, except suicidal behaviors and suicide deaths, for which binary data were extracted. We contacted investigators to request unpublished data, data in the correct format, or addressed other inquiries, with a response rate of 100% (17/17). For the three-arm trial by Chan and colleagues20, we combined the means and standard deviations of the two CBT-I groups for the meta-analyses66. However, for the subgroup analysis comparing delivery formats, we retained the separate means and standard deviations and divided the control group sample size equally across the comparisons.
Risk of bias
Two reviewers (S.B.S. and D.V.) independently and in duplicate assessed the risk of bias for suicidal ideation severity (effect of assignment to intervention) at each timepoint using a version of the Cochrane Risk of Bias 2 (RoB 2) tool67 tailored for psychological intervention trials (Risk of Bias Assistant, version 1.0-0) (preprint)68. Of the 38 outcome-timepoint assessments, 74% (28/38) were performed by both reviewers. Another reviewer (C.T.) performed the remaining assessments using the same tool. The following domains were evaluated: randomization process, deviations from intended interventions, missing outcome data, outcome measurement and selection of reported results. Each domain was rated as ‘low risk’, ‘some concerns’ or ‘high risk’. The overall risk of bias was determined by the least favorable domain rating. Disagreements were resolved through discussion or consultation with additional reviewers (Y.F., M.L.P. and E.H.). All risk-of-bias visualizations were generated using the robvis Shiny app69.
Data synthesis
Meta-analyses were conducted for pairwise comparisons informed by ≥3 RCTs. For suicidal ideation severity, we calculated the RoM70 between the CBT-I group and control groups at post-intervention and follow-ups (1–3, 5–6 and 12 months), along with 95% CIs (see amendment in Supplementary Information, section 17). For the same timepoints, we calculated the SMD for depression severity. The MD was calculated for insomnia severity, which was measured using the Insomnia Severity Index (ISI)71 in all except one trial24 that used the Athens Insomnia Scale72. SMDs were also calculated for insomnia severity to incorporate all available evidence; however, the MD in ISI score was prioritized to facilitate clinical interpretation. For SMDs, Hedges’ g was used as a measure of effect size73. Only end scores comparing intervention and control arms were extracted. Where studies reported outcomes in multiple formats, we prioritized the end score over the change score, and methods accounting for missing outcome data over observed cases. On the basis of the assumption that there is a distribution of true effect sizes rather than a single true effect size, a random-effects model was used for the meta-analyses. The between-study variance (τ2) was estimated using restricted maximum likelihood74, while the CI for the pooled effect was calculated using the DerSimonian and Laird method75. Forest plots were generated to visualize the results. The degree of heterogeneity between studies was assessed using I2. As an additional measure of heterogeneity and to estimate the range of effect sizes in future studies, 95% PIs were calculated76. The presence of potential publication bias (or ‘small-study effects’) for suicidal ideation severity was assessed with a contour-enhanced funnel plot77 and Egger’s test if ≥10 trials were available.
Subgroup analyses were conducted to assess whether treatment effects were moderated by age group (young adults, middle-aged adults and older adults), intervention delivery format (therapist-delivered CBT-I, self-guided digital CBT-I and therapist-guided digital CBT-I), population (university students, community samples and patients) and whether trials recruited participants with recent/current suicidal ideation. Moreover, we performed meta-regressions to examine the percentage of women, post-intervention SMD in depression severity and post-intervention MD in ISI score as moderators of changes in suicidal ideation severity at post-intervention.
To assess the robustness of the synthesized results for suicidal ideation severity, we conducted sensitivity analyses excluding studies with high overall risk of bias, >20% dropout, waitlist control group or a single questionnaire item as a measure of suicidal ideation.
All statistical analyses were conducted in R (version 4.6.1) using the meta (version 8.5-0) package78. A narrative synthesis was undertaken for suicidal behaviors and suicide deaths, given the rarity of events. In addition, hopelessness (k = 2) and studies with non-estimable effects for suicidal ideation severity were synthesized narratively.
Certainty of evidence
One reviewer (C.T.) assessed the certainty of evidence for suicidal ideation severity using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework79, which was reviewed by another reviewer (Y.F.). The GRADEpro GDT tool80 was used for the assessments. The following domains were used for downgrading the evidence certainty: risk of bias, inconsistency, indirectness, imprecision and publication bias79. Certainty was rated as high, moderate, low or very low. Disagreements were resolved through discussion.
Reporting summary
Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.
Data availability
The published data used in the meta-analyses are publicly available via Open Science Framework at https://osf.io/awtfy/. Some of the data used in the meta-analyses are unpublished data provided by other authors and are not included in the datasets because permission to share these data publicly was not obtained from the data providers.
Code availability
The R script used for conducting the analyses is publicly available via Open Science Framework at https://osf.io/awtfy/.
References
Davis Weaver, N. et al. Global, regional, and national burden of suicide, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Public Health 10, e189–e202 (2025).
Kim, S. et al. Global, regional and national trends in suicide mortality rates across 102 countries from 1990 to 2021 with projections up to 2050. Nat. Ment. Health 3, 991–1001 (2025).
De Leo, D. et al. International study of definitions of English-language terms for suicidal behaviours: a survey exploring preferred terminology. BMJ Open 11, e043409 (2021).
Rossom, R. C. et al. Suicidal ideation reported on the PHQ9 and risk of suicidal behavior across age groups. J. Affect. Disord. 215, 77–84 (2017).
Hom, M. A., Stanley, I. H. & Joiner, T. E. Jr. Evaluating factors and interventions that influence help-seeking and mental health service utilization among suicidal individuals: a review of the literature. Clin. Psychol. Rev. 40, 28–39 (2015).
Hallford, D. J. et al. Disclosure of suicidal ideation and behaviours: a systematic review and meta-analysis of prevalence. Clin. Psychol. Rev. 101, 102272 (2023).
Pigeon, W. R., Pinquart, M. & Conner, K. Meta-analysis of sleep disturbance and suicidal thoughts and behaviors. J. Clin. Psychiatry 73, e1160–e1167 (2012).
Pronger, C. E. Insomnia and suicide. Lancet 184, 1356–1359 (1914).
van Straten, A. et al. The prevalence of insomnia disorder in the general population: a meta-analysis. J. Sleep Res. 34, e70089 (2025).
Riemann, D. et al. The European Insomnia Guideline: an update on the diagnosis and treatment of insomnia 2023. J. Sleep Res. 32, e14035 (2023).
Türkmen, C. et al. Cognitive behavioral therapy for insomnia across the spectrum of alcohol use disorder: a systematic review and meta-analysis. Sleep Med. Rev. 80, 102049 (2025).
Hertenstein, E. et al. Cognitive behavioral therapy for insomnia in patients with mental disorders and comorbid insomnia: a systematic review and meta-analysis. Sleep Med. Rev. 62, 101597 (2022).
Darden, M. et al. Cost-effectiveness of digital cognitive behavioral therapy (Sleepio) for insomnia: a Markov simulation model in the United States. Sleep 44, zsaa223 (2020).
Kyle, S. D. et al. Clinical and cost-effectiveness of nurse-delivered sleep restriction therapy for insomnia in primary care (HABIT): a pragmatic, superiority, open-label, randomised controlled trial. Lancet 402, 975–987 (2023).
van Ballegooijen, W. et al. Suicidal ideation and suicide attempts after direct or indirect psychotherapy: a systematic review and meta-analysis. JAMA Psychiatry 82, 31–37 (2025).
Mournet, A. M. & Kleiman, E. M. A systematic review and meta-analysis on the efficacy of sleep interventions to treat suicidal ideation. J. Sleep Res. 33, e14133 (2024).
von Spreckelsen, P. et al. The effect and safety of sleep interventions on suicidal thoughts and behavior—a systematic review and meta-analyses. Sleep Med. X 10, 100145 (2025).
ACTRN12622000067774. A Randomised Controlled Trial of Cognitive Behaviour Therapy for Insomnia Delivered via Videoconferencing on University Students with Poor Sleep https://trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12622000067774 (2022).
Batterham, P. J. et al. Trajectories of change and long-term outcomes in a randomised controlled trial of internet-based insomnia treatment to prevent depression. BJPsych Open 3, 228–235 (2017).
Chan, N. Y. et al. Efficacy of email-delivered versus face-to-face group cognitive behavioral therapy for insomnia in youths: a randomized controlled trial. J. Adolesc. Health 70, 763–773 (2022).
Chen, S. J. et al. Effectiveness of app-based cognitive behavioral therapy for insomnia on preventing major depressive disorder in youth with insomnia and subclinical depression: a randomized clinical trial. PLoS Med. 22, e1004510 (2025).
Crosby, E. S., Troop-Gordon, W. & Witte, T. K. A pilot randomized-controlled trial of Sleep Scholar: a brief, internet-based insomnia intervention for college students. Behav. Ther. 56, 366–380 (2024).
Fagundes, D. et al. Efeito da terapia cognitivo comportamental para insônia na depressão e no suicídio. Revista Eletrônica Acervo Saúde 25, e18270 (2025).
Irwin, M. R. et al. Prevention of incident and recurrent major depression in older adults with insomnia: a randomized clinical trial. JAMA Psychiatry 79, 33–41 (2022).
Kaldo, V. et al. Guided internet cognitive behavioral therapy for insomnia compared to a control treatment—a randomized trial. Behav. Res. Ther. 71, 90–100 (2015).
Kalmbach, D. A. et al. A randomized controlled trial of digital cognitive behavioral therapy for insomnia in pregnant women. Sleep Med. 72, 82–92 (2020).
Kalmbach, D. A. et al. Cognitive-behavioral therapy for insomnia prevents and alleviates suicidal ideation: insomnia remission is a suicidolytic mechanism. Sleep 45, zsac251 (2022).
Nazem, S. et al. Impact of an internet-based insomnia intervention on suicidal ideation and associated correlates in veterans at elevated suicide risk. Transl. Behav. Med. 14, 673–683 (2024).
NCT03365024. Computerized Cognitive Behavioral Treatment for Insomnia: Improving Rural Veteran Access to Evidence-Based Treatment to Reduce Suicide Risk (R-Vets Sleep) https://clinicaltrials.gov/show/NCT03365024 (2017).
NCT04986007. Addressing Nocturnal Sleep/Wake Effects on Risk of Suicide in Older Adults https://clinicaltrials.gov/ct2/show/NCT04986007 (2021).
Osorno, R. A. et al. The effects of a sleep intervention in the early COVID-19 pandemic on insomnia and depressive symptoms: results of a randomized controlled pilot study. J. Psychiatr. Res. 182, 319–328 (2025).
Pigeon, W. R., Funderburk, J. S., Bishop, T. M. & Crean, H. F. Brief cognitive behavioral therapy for insomnia delivered to depressed veterans receiving primary care services: a pilot study. J. Affect. Disord. 217, 105–111 (2017).
Pigeon, W. R., Funderburk, J. S., Cross, W., Bishop, T. M. & Crean, H. F. Brief CBT for insomnia delivered in primary care to patients endorsing suicidal ideation: a proof-of-concept randomized clinical trial. Transl. Behav. Med. 9, 1169–1177 (2019).
Pigeon, W. R., Funderburk, J. S., Bishop, T. M., Cross, W. & Crean, H. F. Brief cognitive behavioral insomnia treatment for primary care veterans at elevated risk for suicide: a randomized clinical trial. Psychother. Psychosom. https://doi.org/10.1159/000550973 (2026).
Sheaves, B. et al. Stabilising sleep for patients admitted at acute crisis to a psychiatric hospital (OWLS): an assessor-blind pilot randomised controlled trial. Psychol. Med. 48, 1694–1704 (2018).
Tamm, S. et al. Emotional processing following digital cognitive behavioral therapy for insomnia in people with depressive symptoms: a randomized clinical trial. JAMA Netw. Open 8, e2461502 (2025).
Souza, K., Sosu, E. M., Thomson, S. & Rasmussen, S. A systematic review of the studies testing the integrated motivational-volitional model of suicidal behaviour. Health Psychol. Rev. 18, 698–722 (2024).
O’Connor, R. C. & Kirtley, O. J. The integrated motivational-volitional model of suicidal behaviour. Phil. Trans. R. Soc. B 373, 20170268 (2018).
Chu, C. et al. Insomnia and suicide-related behaviors: a multi-study investigation of thwarted belongingness as a distinct explanatory factor. J. Affect. Disord. 208, 153–162 (2017).
Van Orden, K. A. et al. The interpersonal theory of suicide. Psychol. Rev. 117, 575–600 (2010).
McCall, W. V. & Black, C. G. The link between suicide and insomnia: theoretical mechanisms. Curr. Psychiatry Rep. 15, 389 (2013).
Perlis, M. L. et al. Nocturnal wakefulness as a previously unrecognized risk factor for suicide. J. Clin. Psychiatry 77, e726–e733 (2016).
Tubbs, A. S., Fernandez, F. X., Grandner, M. A., Perlis, M. L. & Klerman, E. B. The mind after midnight: nocturnal wakefulness, behavioral dysregulation, and psychopathology. Front. Netw. Physiol. 1, 830338 (2022).
Vestergaard, C. L. et al. The effect of sleep-wake intraindividual variability in digital cognitive behavioral therapy for insomnia: a mediation analysis of a large-scale RCT. Sleep 44, zsab118 (2021).
Furukawa, Y. et al. Components and delivery formats of cognitive behavioral therapy for chronic insomnia in adults: a systematic review and component network meta-analysis. JAMA Psychiatry 81, 357–365 (2024).
Schneider, C. L. et al. Become your own SLEEPexpert: design, implementation, and preliminary evaluation of a pragmatic behavioral treatment program for insomnia in inpatient psychiatric care. Sleep Adv. 1, zpaa005 (2020).
Zhou, E. S. et al. Effect of culturally tailored, internet-delivered cognitive behavioral therapy for insomnia in Black women: a randomized clinical trial. JAMA Psychiatry 79, 538–549 (2022).
Changing the narrative in suicide prevention. Nat. Ment. Health 3, 957–958 (2025).
Torok, M. et al. Suicide prevention using self-guided digital interventions: a systematic review and meta-analysis of randomised controlled trials. Lancet Digit. Health 2, e25–e36 (2020).
Rabasco, A. et al. Longitudinal risk of suicide outcomes in people with severe mental illness following an emergency department visit and the effects of suicide prevention treatment. J. Affect. Disord. 347, 477–485 (2024).
Eisner, E. et al. Barriers and facilitators of user engagement with digital mental health interventions for people with psychosis or bipolar disorder: systematic review and best-fit framework synthesis. JMIR Ment. Health 12, e65246 (2025).
Schneider, C. et al. Management of insomnia in inpatient psychiatric care: a clinical practice evaluation. Eur. Arch. Psychiatry Clin. Neurosci. 276, 1847–1854 (2026).
McCall, W. V. et al. Reducing suicidal ideation through insomnia treatment (REST-IT): a randomized clinical trial. Am. J. Psychiatry 176, 957–965 (2019).
De Crescenzo, F. et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet 400, 170–184 (2022).
Wilkinson, S. T. et al. Making progress in clinical trials for suicide prevention: a review. JAMA Psychiatry 82, 420–426 (2025).
Chung, D. T. et al. Suicide rates after discharge from psychiatric facilities: a systematic review and meta-analysis. JAMA Psychiatry 74, 694–702 (2017).
Griffin, E. et al. Suicide risk following hospital attendance with self-harm: a national cohort study in Ireland. Nat. Ment. Health 1, 982–989 (2023).
Kleiman, E. M. et al. Examination of real-time fluctuations in suicidal ideation and its risk factors: results from two ecological momentary assessment studies. J. Abnorm. Psychol. 126, 726–738 (2017).
Rogers, M. L., Bafna, A. & Galynker, I. Comparative clinical utility of screening for suicide crisis syndrome versus suicidal ideation in relation to suicidal ideation and attempts at one-month follow-up. Suicide Life Threat. Behav. 52, 866–875 (2022).
Schuck, A., Calati, R., Barzilay, S., Bloch-Elkouby, S. & Galynker, I. Suicide crisis syndrome: a review of supporting evidence for a new suicide-specific diagnosis. Behav. Sci. Law 37, 223–239 (2019).
Troya, M. I. et al. Suicide rates amongst individuals from ethnic minority backgrounds: a systematic review and meta-analysis. eClinicalMedicine 47, 101399 (2022).
Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br. Med. J. 372, n71 (2021).
Türkmen, C. et al. Cognitive behavioral therapy for insomnia as a suicide prevention strategy: a protocol for a systematic review and meta-analysis. Sleep Adv. 6, zpaf070 (2025).
Haddaway, N. R., Grainger, M. J. & Gray, C. T. Citationchaser: a tool for transparent and efficient forward and backward citation chasing in systematic searching. Res. Synth. Methods 13, 533–545 (2022).
DeepL Translate, next-gen (DeepL GmbH, 2026).
Higgins, J. P., Eldridge, S. & Li, T. Including variants on randomized trials. In Cochrane Handbook for Systematic Reviews of Interventions (eds Higgins, J. P. et al.) 569–593 (Wiley, 2019).
Sterne, J. A. C. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Br. Med. J. 366, l4898 (2019).
Miguel, C. et al. Operationalization of Cochrane’s Risk of Bias 2 Tool (RoB 2) in the context of psychotherapy trials. Preprint at medRxiv https://doi.org/10.1101/2025.06.26.25330349 (2025).
McGuinness, L. A. & Higgins, J. P. T. Risk-of-Bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res. Synth. Methods 12, 55–61 (2021).
Friedrich, J. O., Adhikari, N. K. & Beyene, J. The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: a simulation study. BMC Med. Res. Methodol. 8, 32 (2008).
Bastien, C. H., Vallières, A. & Morin, C. M. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2, 297–307 (2001).
Soldatos, C. R., Dikeos, D. G. & Paparrigopoulos, T. J. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J. Psychosom. Res. 48, 555–560 (2000).
Hedges, L. Distribution theory for Glass’s estimator of effect size and related estimators. J. Educ. Behav. Stat. 6, 107–128 (1981).
Viechtbauer, W. Bias and efficiency of meta-analytic variance estimators in the random-effects model. J. Educ. Behav. Stat. 30, 261–293 (2005).
DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control. Clin. Trials 7, 177–188 (1986).
Veroniki, A. A. et al. Methods to calculate uncertainty in the estimated overall effect size from a random-effects meta-analysis. Res. Synth. Methods 10, 23–43 (2019).
Peters, J. L., Sutton, A. J., Jones, D. R., Abrams, K. R. & Rushton, L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J. Clin. Epidemiol. 61, 991–996 (2008).
Balduzzi, S., Rücker, G. & Schwarzer, G. How to perform a meta-analysis with R: a practical tutorial. Evid. Based Ment. Health 22, 153–160 (2019).
Guyatt, G. H. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br. Med. J. 336, 924–926 (2008).
GRADEpro GDT. GRADEpro Guideline Development Tool [Software] (McMaster University and Evidence Prime, 2024).
Acknowledgements
E.H. is supported by the Swiss National Science Foundation (Ambizione grant number PZ00P1_216430). S.N. is supported by the Japan Science and Technology Agency (JPMJFR234R), the Japan Society for the Promotion of Science (24K00492) and the Japan Agency for Medical Research and Development (JP21zf0127005). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The views expressed are those of the authors and not necessarily those of affiliated organizations. We thank the librarian Dipl.-Bibl. V. Braun from the Library of the Medical Faculty Mannheim, University of Heidelberg, for his assistance in developing the systematic search strategy and managing the records. In addition, we thank S. Nazem, J. Forster, D. Kalmbach, E. Crosby, P. Batterham, M. Grandner, D. L. Fagundes, A. Werner-Seidler, J. Newby, A. N. Goldstein-Piekarski, M. Ahmadi, S. Kyle, K. Tse, S. Jernelöv, K. Blom, V. Kaldo, S. Chen, M. Irwin and R. Olmstead for responding to our inquiries regarding their studies.
Funding
C.T. discloses support for the research of this work from the Liaison Committee for Education, Research and Innovation in Central Norway (project number 10359622). H.K. discloses support for the research and publication of this work from the Liaison Committee for Education, Research and Innovation in Central Norway (project number 10472828). The funder had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Author information
Authors and Affiliations
Department for Research and Development, St. Olavs Hospital PH, Trondheim, Norway
Cagdas Türkmen, Simen B. Saksvik, Daniel Vethe, Cagdas Türkmen & Håvard Kallestad
Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
Cagdas Türkmen
Department of Psychiatry, Faculty of Medicine, University of Geneva, Geneva, Switzerland
Carlotta L. Schneider & Elisabeth Hertenstein
Department of Psychiatry and Psychotherapy, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany
Yuki Furukawa
Department of Neuropsychiatry, University of Tokyo, Tokyo, Japan
Yuki Furukawa, Shunichi Sato, Yusuke Takahashi & Daiki Nagaoka
German Center for Mental Health (DZPG), partner site Munich-Augsburg, Munich, Germany
Yuki Furukawa
Department of Psychiatry, University Medical Center Groningen, Groningen, the Netherlands
Jens H. van Dalfsen
Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta University, Augusta, GA, USA
William V. McCall
Department of Psychiatry, University of Rochester Medical Center, Rochester, NY, USA
Wilfred R. Pigeon
Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA
Andrew S. Tubbs
Behavioral Sleep Medicine Program, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
Michael L. Perlis & Michael Perlis
Department of Psychiatry and Psychotherapy, Medical Center—University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
Dieter Riemann, Kai Spiegelhalder & Keita Kawai
German Sleep Society (DGSM e.V.), Jena, Germany
Dieter Riemann
Østmarka Psychiatric Department, St. Olavs Hospital PH, Trondheim, Norway
Knut Langsrud
Department of Mental Health, Norwegian University of Science and Technology, Trondheim, Norway
Håvard Kallestad
Graduate School of Education, Joetsu University of Education, Joetsu, Japan
Shintaro Hara
Awarefy Mental Research Institute, Awarefy Inc., Tokyo, Japan
Hikari N. Takashina
Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan
Kota Imai
International Institute for Integrative Sleep Medicine (WPI-IIIS), Tsukuba Institute for Advanced Research (TIAR), University of Tsukuba, Ibaraki, Japan
Azusa Ishii, Shun Nakajima, Makoto Nishimura, Hiroku Noma & Masatsugu Sakata
Department of Health Promotion and Behavioral Sciences, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan
Masami Ito, Shino Kikuchi, Rie Toyomoto & Masatsugu Sakata
Center for Psycho-Oncology and Palliative Care, Core Laboratory, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Shino Kikuchi
Institute of Medicine, University of Tsukuba, Ibaraki, Japan
Shun Nakajima
Department of Neurodevelopmental Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Masatsugu Sakata
Department of Medical Education, Graduate School of Medicine, University of Toyama, Toyama, Japan
Seina Shinno
Department of Clinical, Neuro and Developmental Psychology, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
Annemieke van Straten
Department of Psychology and Humanities, Edogawa University, Nagareyama, Japan
Ryuichiro Yamamoto
Research Center for Social Science and Medicine, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
Daiki Nagaoka
Authors
- Cagdas Türkmen
- Carlotta L. Schneider
- Yuki Furukawa
- Simen B. Saksvik
- Daniel Vethe
- Jens H. van Dalfsen
- William V. McCall
- Wilfred R. Pigeon
- Andrew S. Tubbs
- Michael L. Perlis
- Dieter Riemann
- Kai Spiegelhalder
- Knut Langsrud
- Håvard Kallestad
- Elisabeth Hertenstein
Consortia
SLEEPI Investigators
- Cagdas Türkmen
- , Shintaro Hara
- , Hikari N. Takashina
- , Kota Imai
- , Azusa Ishii
- , Masami Ito
- , Keita Kawai
- , Shino Kikuchi
- , Shun Nakajima
- , Makoto Nishimura
- , Hiroku Noma
- , Rie Toyomoto
- , Masatsugu Sakata
- , Shunichi Sato
- , Seina Shinno
- , Yusuke Takahashi
- , Annemieke van Straten
- , Ryuichiro Yamamoto
- , Daiki Nagaoka
- , Michael Perlis
- , Yuki Furukawa
- & Elisabeth Hertenstein
Contributions
C.T. is the guarantor of this review. C.T., C.L.S., Y.K., J.H.v.D., W.V.M., W.R.P., A.S.T., M.L.P., D.R., K.S., K.L., H.K. and E.H. conceptualized the study. C.T., C.L.S., Y.K., J.H.v.D., W.V.M., W.R.P., A.S.T., M.L.P., D.R., K.S., K.L., H.K. and E.H. developed the methodology. C.T. and a librarian built the main search strategy. C.T. and C.L.S. performed screening, and E.H. and M.L.P. participated as reviewers to resolve conflicts. D.V., S.B.S. and C.T. performed the risk-of-bias assessments, and Y.F., M.L.P. and E.H. participated as reviewers to resolve conflicts. C.T. performed certainty of evidence assessments, which were reviewed by Y.F. C.T. and C.L.S. extracted the data. C.T., C.L.S. and E.H. verified the data. C.T. conducted the statistical analyses with input from Y.F. C.T. wrote the first draft. E.H. provided supervision for the study. All authors reviewed, edited and approved the final draft. All authors had full access to the data in the study and had final responsibility for the decision to submit for publication.
Corresponding author
Correspondence to Håvard Kallestad.
Ethics declarations
Competing interests
Y.F. has authored multiple academic papers, books and articles on cognitive behavioral therapy for insomnia and has received honoraria for lectures and supervisory roles. H.N.T. is employed by Awarefy, Inc., a company that develops mental health applications based on cognitive behavioral therapy. S.N., a specialist in cognitive behavioral therapy and sleep medicine, reports receiving research funding and donations from Amazon.com, Inc., Tsukuba City, Nomura Real Estate Development Co., Ltd., S’UIMIN Inc., NTT PARAVITA and Mitsubishi Electric Corporation. M.S. has authored multiple academic papers, books and articles on cognitive behavioral therapy for insomnia and is employed in the Department of Neurodevelopmental Disorders, Nagoya City University Graduate School of Medicine, which is an endowment department supported by the City of Nagoya, and has received personal fee from SONY and Daiichi-Sankyo outside submitted work. W.V.M. is a scientific advisor and receives honoraria or equity options from Idorsia, Haleon, LivaNova, Axon Medical Technologies, AlzaTV and Carelon. D.R. is now speaker of the board of the German Sleep Society (non-profit organization) and receives monthly honoraria for this task. D.R. is a member of the Executive Board of FAVT (Freiburger Ausbildungsinstitut für Verhaltenstherapie/Freiburg Institute for Behavioral Therapy; non-profit organization). In this function, he receives honoraria for running examinations, giving lectures, attending board meetings and participating in the selection of candidates. D.R. was editor-in-chief of the Journal of Sleep Research, which is owned by the European Sleep Research Society (non-profit organization)—he received monthly payments for this task until December 2025. D.R. receives royalties for authored books and book chapters from several publishing companies (Elsevier, Hogrefe, Kohlhammer, Wiley and Sons, and so on). The published materials mainly deal with insomnia and its treatment. D.R. frequently lectures at conferences, meetings and seminars, mostly invited by the organizing bodies—sometimes honoraria are paid for his engagement and usually travel costs (if traveling is involved) are covered. Most of his talks deal with aspects of insomnia. In the last 12 months, D.R. received lecturing honoraria also from Novartis and Idorsia. D.R. receives honoraria from GAIA Group (Germany), Meinstresscoach (Switzerland), /Mind (Germany), 7Mind (Germany), HelloBetter (Germany), Sympatient (Germany) and X-Trodes (Israel) for advising on the development of internet-based approaches to insomnia treatment and development of new measurement devices. R.Y. has authored multiple academic papers, books and articles on cognitive behavioral therapy for insomnia. The Edogawa University Sleep Research Institute, to which R.Y. belongs, has received research funding from Paramount Bed Co., Ltd., outside the submitted work. The other authors declare no competing interests.
Peer review
Peer review information
Nature Mental Health thanks William Saunders, Jim Schmeckenbecher and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Türkmen, C., Schneider, C.L., Furukawa, Y. et al. Systematic review and meta-analysis of cognitive behavioral therapy for insomnia as a suicide prevention strategy. Nat. Mental Health (2026). https://doi.org/10.1038/s44220-026-00743-0
Received: 13 April 2026
Accepted: 21 September 2026
Published: 23 October 2026
Version of record: 23 October 2026
DOI: https://doi.org/10.1038/s44220-026-00743-0
来源:Nature 健康护理主题 · nature.com